Page last updated: 2024-10-29

ifosfamide and Thrombopenia

ifosfamide has been researched along with Thrombopenia in 84 studies

Research Excerpts

ExcerptRelevanceReference
"The objective of this Phase I dose escalation study was to explore the safety and tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy."9.17Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. ( Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A, 2013)
"5 g m(-2), carboplatin 100 mg m(-2) and etoposide 150 mg m(-2), days 1-4, q 28 days, G-CSF 5 microg kg(-1) starting from day 6) alone and in combination with regional hyperthermia (RHT) in soft tissue sarcoma (STS) refractory to previous standard doxorubicin-ifosfamide-based chemotherapy."9.11Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. ( Abdel-Rahman, S; Fahn, W; Fiegl, M; Issels, RD; Schlemmer, M; Wendtner, CM, 2004)
"The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear."9.11Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005)
"Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery."9.10Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002)
"The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma."9.10Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002)
"Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma."9.08Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. ( Ben-Shahar, M; Epelbaum, R; Haim, N, 1995)
"Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship."9.08High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998)
"This study investigated the feasibility and efficacy of doxorubicin dose-escalated chemotherapy in combination with ifosfamide in patients with malignant mesothelioma."9.07A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. ( Corthouts, B; Dirix, LY; Prové, A; Schrijvers, D; van Marck, E; van Meerbeeck, J; van Oosterom, AT; Vermeire, P, 1994)
"To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen)in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy."7.81[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. ( Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S, 2015)
"Recurrent and refractory neuroblastoma responds well to chemotherapy regimen of ifosphamide plus carboplatin."7.73[Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006)
"Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor."7.70[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998)
"A total of 33 patients (median age, 44 years) with high-grade, adult soft-tissue sarcoma were treated with etoposide given at 600 mg/m2 in a 72-h continuous infusion and ifosfamide given at 1500 mg/m2 per day for 3 days every 3 weeks."7.69Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. ( Saeter, G; Solheim, OP; Talle, K, 1995)
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma."7.68Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J, 1990)
"In advanced soft tissue sarcomas of adults, single-agent doxorubicin is still the standard chemotherapy against which more intensive or new drug treatments should be compared."6.68Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. ( Buesa, J; Casali, P; Mouridsen, H; Rankin, E; Santoro, A; Somers, R; Spooner, D; Steward, W; Tursz, T; Verweij, J, 1995)
"The objective of this Phase I dose escalation study was to explore the safety and tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy."5.17Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. ( Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A, 2013)
"5 g m(-2), carboplatin 100 mg m(-2) and etoposide 150 mg m(-2), days 1-4, q 28 days, G-CSF 5 microg kg(-1) starting from day 6) alone and in combination with regional hyperthermia (RHT) in soft tissue sarcoma (STS) refractory to previous standard doxorubicin-ifosfamide-based chemotherapy."5.11Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. ( Abdel-Rahman, S; Fahn, W; Fiegl, M; Issels, RD; Schlemmer, M; Wendtner, CM, 2004)
"The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear."5.11Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005)
"Cohorts of six patients with sarcoma (66 assessable patients) were treated sequentially with doxorubicin and ifosfamide (AI), with rhTPO by a fixed dose and varying schedules being administered before and/or after chemotherapy in cycle 2 and subsequent cycles."5.10Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. ( Benjamin, RS; Broemeling, LD; Broxmeyer, HE; Bueso-Ramos, C; Burgess, A; Folloder, J; Papadopolous, N; Patel, S; Vadhan-Raj, S, 2003)
"The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma."5.10Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002)
"Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery."5.10Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002)
"Twenty-nine patients diagnosed with recurrent neuroblastoma or PNET were treated with a combination chemotherapy regimen of cisplatin, 160 mg/m(2)/96 hours; doxorubicin, 40 mg/m(2)/96 hours; and escalated doses of etoposide and ifosfamide."5.09A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma. ( Fernandez, MC; Gerbing, RR; Krailo, MD; Matthay, KK, 2000)
"Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship."5.08High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998)
"Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma."5.08Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. ( Ben-Shahar, M; Epelbaum, R; Haim, N, 1995)
" At the original dose of cisplatin, etoposide, and ifosfamide without G-CSF, 55% of cycles resulted in neutropenia and 38% in thrombocytopenia (dose intensity = 0."5.08Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer. ( Fanning, J; Hilgers, RD, 1996)
"This study investigated the feasibility and efficacy of doxorubicin dose-escalated chemotherapy in combination with ifosfamide in patients with malignant mesothelioma."5.07A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. ( Corthouts, B; Dirix, LY; Prové, A; Schrijvers, D; van Marck, E; van Meerbeeck, J; van Oosterom, AT; Vermeire, P, 1994)
"To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen)in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy."3.81[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. ( Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S, 2015)
"AEs observed during 1 of 3 randomized chemotherapy regimens (vincristine, dactinomycin, and cyclophosphamide [VAC]; vincristine, dactinomycin, and ifosfamide [VAI]; or vincristine, ifosfamide, and etoposide [VIE]) in the Fourth Intergroup Rhabdomyosarcoma Study were recorded."3.78Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. ( Anderson, JR; Dasgupta, R; Gupta, AA; Hawkins, DS; Indelicato, DJ; Pappo, AS; Spunt, SL, 2012)
"The stage-by-stage prognosis for cervical cancer patients has not improved in the past decades."3.77Neoadjuvant therapy for cervical cancer. ( Achterrath, W; Eiermann, W; Kuehnle, H; Meerpohl, HG, 1992)
"Recurrent and refractory neuroblastoma responds well to chemotherapy regimen of ifosphamide plus carboplatin."3.73[Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006)
"Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor."3.70[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998)
"A total of 33 patients (median age, 44 years) with high-grade, adult soft-tissue sarcoma were treated with etoposide given at 600 mg/m2 in a 72-h continuous infusion and ifosfamide given at 1500 mg/m2 per day for 3 days every 3 weeks."3.69Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. ( Saeter, G; Solheim, OP; Talle, K, 1995)
"Twelve patients with relapsed or refractory malignant lymphoma were treated with IMV-triple P regimen consisting of ifosfamide (IFM), mitoxantrone (MIT), vindesine (VDS), pepleomycin (PEP), procarbazine (PCZ) and prednisolone (PDN)."3.68[Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma]. ( Arai, N; Hara, A; Shirai, T; Umeda, M, 1991)
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma."3.68Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J, 1990)
"This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma."2.87Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. ( Claret, L; Copeland, AR; Fanale, MA; Fayad, LE; Feng, L; Fowler, N; Hagemeister, FB; Hu, B; Nastoupil, LJ; Neelapu, S; Nieto, Y; Oki, Y; Rodriguez, MA; Romaguera, J; Samaniego, F; Turturro, F; Westin, JR; Younes, A, 2018)
"Cancer patients with solid tumors that experienced post chemotherapy thrombocytopenia with a nadir of < = 80,000 platelets/ml were eligible for this clinical trial."2.75Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia. ( Daehler, M; Grutsch, JF; Gupta, D; Hall, JL; Levin, RD; Lis, CG, 2010)
" Sequential dose intense ifosfamide, etoposide, carboplatin +/- rituximab was more toxic and no more effective than the same drugs given in a conventional fashion."2.74Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. ( Beaven, AW; Chao, N; Gabriel, DA; Garcia, RA; Gockerman, JP; Moore, DT; Rizzieri, DA; Serody, JS; Shea, TC, 2009)
"Neutropenia was the major toxicity."2.71Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. ( Ambaum, B; Beijnen, JH; Groenewegen, G; Herben, VM; Jansen, S; Kerbusch, T; Mathôt, RA; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Voest, EE, 2004)
"Grade 3-4 neutropenia was the dose limiting toxicity, observed in 36% of patients."2.71Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. ( Brunetti, C; Cassano, G; Colucci, G; Galetta, D; Gebbia, V; Germano, D; Giampaglia, M; Guida, M; Izzi, G; Lorusso, V; Nettis, G; Silvestris, N; Spada, M, 2005)
"Grade 3 thrombocytopenia was observed in five cases (36%)."2.71Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. ( Kitamura, T; Kume, H; Matsumoto, S; Nishimatsu, H; Okamoto, N; Suzuki, M; Takahashi, S; Tomita, K, 2005)
"To find the maximum tolerated dose for ifosfamide in combination with paclitaxel and carboplatin in small-cell lung cancer patients (SCLC), who are resistant to cyclophosphamide, doxorubicin and etoposide (CDE)."2.70Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancer. ( Beijnen, JH; Groen, HJ; Kerbush, T; Sleijfer, DT; Smit, EF; van Putten, JW; van Rijswijk, R, 2001)
"Grade 3-4 neutropenia was experienced by 9 (27%) patients, grade 3 4 anemia by 6 (18%) and grade 3-4 thrombocytopenia by 4 (12%)."2.70Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. ( Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kalofonos, H; Kiamouris, C; Nicolaides, C; Pectasides, D; Visvikis, A; Xiros, N, 2001)
" Our trial failed to demonstrate a significant improvement in response or survival when patients with metastatic NSCLC were treated, in addition to ifosfamide and mitomycin, by combination of moderate dosages of cisplatin and carboplatin instead of moderate dosage of cisplatin alone."2.69Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. ( Alexopoulos, CG; Baumöhl, J; Berghmans, T; Florin, MC; Klastersky, J; Koumakis, G; Lafitte, JJ; Mommen, P; Ninane, V; Paesmans, M; Schmerber, J; Sculier, JP; Thiriaux, J; Zacharias, C, 2000)
" We report the use of a continuous high dose infusion of ïfosfamide at a dose of 9g/m(2) over 3 days in combination with etoposide and epirubicin followed by autologous stem cell transplant with either BEAM or Melphalan/VP16 conditioning in this difficult group."2.69High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy. ( Angus, B; Carey, PJ; Finney, RD; Galloway, MJ; Goff, DK; Haynes, A; Jackson, GH; Lennard, AL; Leonard, RC; McQuaker, IG; Proctor, SJ; Russell, N; Taylor, PR; Windebank, K, 2000)
"In advanced soft tissue sarcomas of adults, single-agent doxorubicin is still the standard chemotherapy against which more intensive or new drug treatments should be compared."2.68Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. ( Buesa, J; Casali, P; Mouridsen, H; Rankin, E; Santoro, A; Somers, R; Spooner, D; Steward, W; Tursz, T; Verweij, J, 1995)
" The dosage of paclitaxel was escalated from 75 to 225 mg/m2."2.68A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. ( Carey, RW; Elias, AD; Grossbard, ML; Jacobs, C; Jauss, S; Kwiatkowski, DJ; Lynch, TJ; Shulman, LN; Strauss, GM; Sugarbaker, DJ, 1995)
"Twenty-three patients with chronic myelogenous leukemia in early chronic phase (ECP) and not previously treated with alpha-interferon (IFN-alpha) (10 patients), in ECP but pretreated with IFN-alpha (<12 months) (seven patients) and in late chronic phase (LCP) pretreated with IFN-alpha (>12 months) (six patients) underwent autografting with Philadelphia (Ph) chromosome-negative blood progenitor cells (BPCs) (20 patients), or partially/totally Ph-positive BPCs (three patients), previously mobilized during the early phase of recovery after aplasia induced by intensive chemotherapy."2.68High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. ( Benvenuto, F; Carella, AM; Carlier, P; Chimirri, F; Dejana, A; Ferrara, RA; Florio, G; Frassoni, F; Gatti, AM; Incagliato, M; Lerma, E; Piaggio, G; Pitto, A; Podestà, M; Pollicardo, N; Prencipe, E; Soracco, M; Valbonesi, M; Vassallo, F; Vimercati, R, 1996)
"The tolerance of escalating targeted doses of carboplatin combined with ifosfamide (IFOS)/etoposide (VP-16) (ICE) was assessed in children with recurrent solid tumors."2.67Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. ( Bowman, LC; Douglass, E; Furman, W; Hudson, M; Marina, NM; Meyer, W; Rodman, J; Santana, VM; Shema, SJ; Wilimas, J, 1993)
"Paclitaxel is a potent anticancer agent against a variety of solid cancers."1.33[Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer]. ( Kawauchi, A; Mikami, K; Miki, T; Mizutani, Y; Nakamura, T; Nakanishi, H; Nomoto, T, 2006)
"Seventeen patients had non-Hodgkin lymphoma (NHL) and 13 patients had Hodgkin disease (HD)."1.33IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. ( Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A, 2005)
"Febrile neutropenia was observed in 5 patients (41."1.32[Paclitaxel, ifosfamide, nedaplatin (TIN) for patients with metastatic urothelial cancer]. ( Demura, T; Harabayashi, T; Ishikawa, R; Koyanagi, T; Mitsuhashi, K; Murakumo, M; Seki, H; Shinohara, N; Suzuki, S; Toyota, H, 2004)
"Paclitaxel was given at a dose of 120 mg/m2 to five patients, 135 mg/m2 to five patients, 150 mg/m2 to three patients, and 175 mg/m2 to 11 patients."1.29Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. ( Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L, 1996)

Research

Studies (84)

TimeframeStudies, this research(%)All Research%
pre-19904 (4.76)18.7374
1990's31 (36.90)18.2507
2000's35 (41.67)29.6817
2010's11 (13.10)24.3611
2020's3 (3.57)2.80

Authors

AuthorsStudies
Zhang, B2
Zhang, Y2
Li, R1
Li, J1
Lu, X1
Sang, W1
Shi, M1
Yang, J2
Cao, J1
Xu, L1
Yan, D1
Yao, M1
Liu, H1
Li, W2
Sun, K1
Song, X1
Sun, C1
Jiao, J1
Qin, Y2
Sang, T1
Ma, Y1
Wu, M1
Gao, X1
Cheng, H1
Yan, Z1
Li, D1
Sun, H1
Zhu, F1
Wang, Y1
Zeng, L1
Li, Z1
Zheng, J1
Xu, K1
Rainusso, N1
Gruner, SE1
Hernandez, JA1
Hu, B1
Younes, A1
Westin, JR1
Turturro, F1
Claret, L1
Feng, L1
Fowler, N1
Neelapu, S1
Romaguera, J1
Hagemeister, FB1
Rodriguez, MA1
Samaniego, F1
Fayad, LE1
Copeland, AR1
Nastoupil, LJ1
Nieto, Y1
Fanale, MA1
Oki, Y1
Chawla, SP1
Staddon, A1
Hendifar, A1
Messam, CA1
Patwardhan, R1
Kamel, YM1
Evens, AM1
Carson, KR1
Kolesar, J1
Nabhan, C1
Helenowski, I1
Islam, N1
Jovanovic, B1
Barr, PM1
Caimi, PF1
Gregory, SA1
Gordon, LI1
Kakutani, S1
Fukuhara, H1
Taguchi, S1
Nagata, M1
Niimi, A1
Hattori, M1
Miyazaki, H1
Fujimura, T1
Nakagawa, T1
Kume, H2
Igawa, Y1
Homma, Y1
Fayad, L1
Ansell, SM1
Advani, R1
Coiffier, B1
Stuart, R1
Bartlett, NL1
Forero-Torres, A1
Kuliczkowski, K1
Belada, D1
Ng, E1
Drachman, JG1
Yin, ZM1
Yu, AJ1
Wu, MJ1
Fang, J1
Liu, LF1
Zhu, JQ1
Yu, H1
Hu, S1
He, X1
Dong, M2
Jia, B1
Zhou, S1
Yang, S2
Zhang, C1
Liu, P2
Gui, L1
Liu, XM1
Wang, HQ1
Zhang, HL1
Qiu, LH1
Li, LF1
Cui, XZ1
Liu, PF1
Hao, XS1
Shea, TC1
Beaven, AW1
Moore, DT1
Serody, JS1
Gabriel, DA1
Chao, N1
Gockerman, JP1
Garcia, RA1
Rizzieri, DA1
Sun, XF2
Zhen, ZJ2
Xiang, XJ1
Ling, JY2
Peng, RJ1
Xia, Y2
Zheng, L1
Luo, WB1
Lin, H1
Guan, ZZ1
Specenier, P1
Rasschaert, M1
Van den Brande, J1
Dyck, J1
Schrijvers, D2
Huizing, MT1
Vermorken, JB1
Levin, RD1
Daehler, M1
Grutsch, JF1
Hall, JL1
Gupta, D1
Lis, CG1
Hong, S1
Shin, SJ1
Jung, M1
Jeong, J1
Lee, YJ1
Shin, KH1
Roh, JK1
Rha, SY1
Gupta, AA1
Anderson, JR1
Pappo, AS1
Spunt, SL1
Dasgupta, R1
Indelicato, DJ1
Hawkins, DS1
Blot, E1
Decaudin, D1
Veyradier, A1
Bardier, A1
Zagame, OL1
Pouillart, P1
Arellano-Rodrigo, E1
López-Guillermo, A1
Bessell, EM1
Nomdedeu, B1
Montserrat, E1
Graus, F1
Vadhan-Raj, S2
Patel, S1
Bueso-Ramos, C1
Folloder, J1
Papadopolous, N1
Burgess, A1
Broemeling, LD1
Broxmeyer, HE1
Benjamin, RS1
Suzuki, S1
Shinohara, N1
Harabayashi, T1
Seki, H1
Murakumo, M1
Ishikawa, R1
Demura, T1
Mitsuhashi, K1
Toyota, H1
Koyanagi, T1
Kerbusch, T1
Groenewegen, G1
Mathôt, RA1
Herben, VM1
ten Bokkel Huinink, WW1
Swart, M1
Ambaum, B1
Rosing, H1
Jansen, S1
Voest, EE1
Beijnen, JH2
Schellens, JH1
Fiegl, M1
Schlemmer, M1
Wendtner, CM1
Abdel-Rahman, S1
Fahn, W1
Issels, RD1
Cairo, MS2
Davenport, V1
Bessmertny, O1
Goldman, SC1
Berg, SL1
Kreissman, SG1
Laver, J1
Shen, V1
Secola, R1
van de Ven, C1
Reaman, GH1
Worden, FP1
Taylor, JM1
Biermann, JS1
Sondak, VK1
Leu, KM1
Chugh, R1
McGinn, CJ1
Zalupski, MM1
Baker, LH1
Takahashi, S1
Suzuki, M1
Matsumoto, S1
Okamoto, N1
Nishimatsu, H1
Tomita, K1
Kitamura, T1
Zhou, SY1
Shi, YK1
He, XH1
Zhang, P1
Huang, DZ1
Yang, JL1
Zhang, CG1
Feng, FY1
Abali, H1
Oyan, B1
Koc, Y1
Kars, A1
Barista, I1
Uner, A1
Turker, A1
Demirkazik, F1
Tekin, F1
Tekuzman, G1
Kansu, E1
Chamorey, E1
Gressin, R1
Peyrade, F1
Rossi, JF2
Lepeu, G1
Foussard, C1
Harrousseau, JL1
Fabbro, M1
Richard, B1
Delwail, V1
Maisonneuve, H1
Vilque, JP1
Thyss, A1
Lorusso, V2
Gebbia, V1
Spada, M1
Guida, M1
Cassano, G1
Brunetti, C1
Germano, D1
Nettis, G1
Izzi, G1
Galetta, D1
Giampaglia, M1
Silvestris, N1
Colucci, G1
Fan, Y1
Huang, ZY1
Luo, LH1
Yu, HF1
Nomoto, T1
Mizutani, Y1
Mikami, K1
Nakamura, T1
Nakanishi, H1
Kawauchi, A1
Miki, T1
Li, EX1
Zhang, YT1
Shang, JT1
Xu, Z1
Geng, Y1
Li, SM1
Shi, F1
Wu, YY1
Wang, ZH1
Bo, LJ1
Liang, AB1
Liu, B1
Chen, YH1
Wang, F1
Jin, XP1
Morgan, LR1
Harrison, EF1
Hawke, JE1
Hunter, HL1
Costanzi, JJ1
Plotkin, D1
Tucker, WG1
Worrall, PM1
Beyer, J1
Schwella, N1
Zingsem, J1
Strohscheer, I1
Schwaner, I1
Oettle, H1
Serke, S1
Huhn, D1
Stieger, W1
Saeter, G1
Talle, K1
Solheim, OP1
Crawford, J1
George, M1
Haim, N1
Ben-Shahar, M1
Epelbaum, R1
Strauss, GM1
Lynch, TJ1
Elias, AD1
Jacobs, C1
Kwiatkowski, DJ1
Shulman, LN1
Carey, RW1
Grossbard, ML1
Jauss, S1
Sugarbaker, DJ1
Santoro, A2
Tursz, T1
Mouridsen, H1
Verweij, J2
Steward, W1
Somers, R2
Buesa, J1
Casali, P1
Spooner, D1
Rankin, E1
Dirix, LY1
van Meerbeeck, J1
Corthouts, B1
Prové, A1
van Marck, E1
Vermeire, P1
van Oosterom, AT2
Bokemeyer, C1
Schmoll, HJ1
Harstrick, A1
Illiger, HJ1
Metzner, B1
Räth, U1
Hohnloser, J1
Clemm, C1
Berdel, W1
Siegert, W1
Filtenborg, TA1
Hansen, HH2
Aage Engelholm, S1
Rørth, M1
Graziano, SL1
Herndon, JE1
Richards, F1
DiFino, S1
Modeas, C1
Duggan, DB1
Green, MR1
Marina, NM1
Rodman, J1
Shema, SJ1
Bowman, LC1
Douglass, E1
Furman, W1
Santana, VM1
Hudson, M1
Wilimas, J1
Meyer, W1
Magrath, I1
Adde, M1
Shad, A1
Venzon, D1
Seibel, N1
Gootenberg, J1
Neely, J1
Arndt, C1
Nieder, M1
Jaffe, E1
Wittes, RA1
Horak, ID1
Carella, AM1
Chimirri, F1
Podestà, M1
Pitto, A1
Piaggio, G1
Dejana, A1
Lerma, E1
Pollicardo, N1
Vassallo, F1
Soracco, M1
Benvenuto, F1
Valbonesi, M1
Carlier, P1
Vimercati, R1
Prencipe, E1
Gatti, AM1
Ferrara, RA1
Incagliato, M1
Florio, G1
Frassoni, F1
Chang, AY1
Boros, L1
Garrow, GC1
Asbury, RF1
Hui, L1
Lokich, J1
Anderson, N1
Moore, C1
Bern, M1
Coco, F1
Dow, E1
Wexler, LH1
DeLaney, TF1
Tsokos, M1
Avila, N1
Steinberg, SM1
Weaver-McClure, L1
Jacobson, J1
Jarosinski, P1
Hijazi, YM1
Balis, FM1
Horowitz, ME1
Fanning, J1
Hilgers, RD1
Glisson, B2
Lee, JS2
Palmer, J1
Fossella, F2
Shin, DM2
Murphy, WK2
Perez-Soler, R2
Hong, WK1
Komaki, R1
Kurie, J1
Schea, R1
Hirota, T1
Takeuchi, M1
Iwata, A1
Kitagawa, S1
Sato, T1
Konno, K1
Sawada, K1
Kobayashi, S1
Hamaguchi, N1
Agata, H1
Katano, N1
Fujimoto, T1
Leone, B1
Di Vagno, G1
Manzione, L1
Palmeri, S1
Vallejo, C1
Machiavelli, M1
Nacci, G1
Bilancia, D1
Leonardi, V1
Catino, A1
Gargano, G1
Loverro, G1
Selvaggi, L1
De Lena, M1
De Pas, T2
De Braud, F1
Orlando, L1
Nolè, F1
Munzone, E1
Zampino, MG1
Fazio, N1
Aapro, MS1
Goldhirsch, A1
van de Velde, H1
Bosquée, L1
Weynants, P1
Canon, JL1
Rosier, JF1
Humblet, Y1
Soulié, P1
Garrino, C1
Bensmaïne, MA1
Bekradda, M1
Brain, E1
Di Palma, M1
Goupil, A1
Misset, JL1
Cvitkovic, E1
Kosmas, C1
Tsavaris, NB1
Polyzos, A1
Malamos, NA1
Katsikas, M1
Antonopoulos, MJ1
Fernandez, MC1
Krailo, MD1
Gerbing, RR1
Matthay, KK1
Boni, C1
Bisagni, G1
Savoldi, L1
Moretti, G1
Rondini, E1
Sassi, M1
Zadro, A1
Franciosi, V1
Pazzola, A1
Vignoli, R1
Banzi, MC1
Pajetta, V1
Sculier, JP1
Lafitte, JJ1
Paesmans, M1
Thiriaux, J1
Alexopoulos, CG1
Baumöhl, J1
Schmerber, J1
Koumakis, G1
Florin, MC1
Zacharias, C1
Berghmans, T1
Mommen, P1
Ninane, V1
Klastersky, J1
Jackson, GH1
Angus, B1
Carey, PJ1
Finney, RD1
Galloway, MJ1
Goff, DK1
Haynes, A1
Lennard, AL1
Leonard, RC1
McQuaker, IG1
Proctor, SJ1
Russell, N1
Windebank, K1
Taylor, PR1
Chen, YM1
Perng, RP1
Whang-Peng, J1
Wu, HW1
Lin, WC1
Tsai, CM1
Johnson, PW1
Muers, MF1
Peake, MD1
Poulter, KM1
Gurney, EM1
Napp, VV1
Hepburn, PM1
Brown, JM1
Tognoni, A1
Pensa, F1
Vaira, F1
Vigani, A1
Bancalari, L1
Fiasella, L1
Maggiani, R1
Canessa, P1
Pronzato, P1
Fulda, S1
Fichtner, I1
Hero, B1
Berthold, F1
van Putten, JW1
Kerbush, T1
Smit, EF1
van Rijswijk, R1
Sleijfer, DT1
Groen, HJ1
Lee, EJ1
Petroni, GR1
Schiffer, CA1
Freter, CE1
Johnson, JL1
Barcos, M1
Frizzera, G1
Bloomfield, CD1
Peterson, BA1
Pectasides, D1
Aravantinos, G1
Kalofonos, H1
Kiamouris, C1
Bafaloukos, D1
Xiros, N1
Nicolaides, C1
Visvikis, A1
Dimopoulos, MA1
Goorin, AM1
Harris, MB1
Bernstein, M1
Ferguson, W1
Devidas, M1
Siegal, GP1
Gebhardt, MC1
Schwartz, CL1
Link, M1
Grier, HE1
Edmonson, JH1
Petersen, IA1
Shives, TC1
Mahoney, MR1
Rock, MG1
Haddock, MG1
Sim, FH1
Maples, WJ1
O'Connor, MI1
Gunderson, LL1
Foo, ML1
Pritchard, DJ1
Buckner, JC1
Stafford, SL1
Nelson, RL1
Creaven, PJ1
Cohen, MH1
Fossieck, BE1
Lund, B1
Hansen, OP1
Hansen, M1
Kuehnle, H1
Meerpohl, HG1
Eiermann, W1
Achterrath, W1
Arai, N1
Hara, A1
Umeda, M1
Shirai, T1
Schütte, J1
Mouridsen, HT1
Stewart, W1
Blackledge, G1
Dombernowsky, P1
Thomas, D1
Smith, IE1
Perren, TJ1
Ashley, SA1
Woodiwiss, J1
Forgeson, GV1
Yarnold, JR1
Ford, HT1
Pujol, JL1
Le Chevalier, T1
Daurès, JP1
Rouanet, P1
Douillard, JY1
Dubois, JB1
Arriagada, R1
Mary, H1
Godard, P1
Einhorn, LH2
Loehrer, PJ1

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Sequential Infusion of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor(CAR) T Cells Against Relapsed and Refractory B-cell Lymphoma[NCT03207178]Phase 1/Phase 220 participants (Anticipated)Interventional2017-03-01Recruiting
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen[NCT00358540]Phase 118 participants (Actual)Interventional2006-06-01Completed
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma[NCT00392990]Phase 225 participants (Actual)Interventional2007-02-06Completed
A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL)[NCT00529503]Phase 2151 participants (Actual)Interventional2007-09-30Terminated
Phase II Dose of Escalation Design to Investigate the Therapeutic Role of RNA Fragments in the Protection of Platelet Production During Chemotherapy[NCT01163110]Phase 132 participants (Actual)Interventional2004-03-31Completed
Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920]Phase 230 participants (Anticipated)Interventional2019-10-01Not yet recruiting
A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas[NCT01830153]Phase 241 participants (Actual)Interventional2010-04-30Completed
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499]Phase 253 participants (Actual)Interventional2010-01-31Completed
Phase II Prospective Study With BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas, After Anthracycline-based Therapy[NCT00406601]Phase 269 participants (Actual)Interventional2006-11-30Completed
Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus[NCT03342300]Phase 2/Phase 30 participants (Actual)Interventional2017-11-06Withdrawn (stopped due to No participants enrolled)
Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193]Phase 220 participants (Anticipated)Interventional2006-08-31Completed
HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN[NCT00002494]Phase 2134 participants (Actual)Interventional1992-05-31Completed
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473]Phase 2100 participants (Anticipated)Interventional2014-01-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Overall Survival (OS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen

Overall Survival (OS) of patients with Burkitt's and Burkitt-like Lymphoma/Leukemia treated with modified Magrath regimen. OS is defined from the first dose of study drug to the time of death for any reason. (NCT00392990)
Timeframe: At 2 years from treatment initiation Median follow up 34 months (range 15-45)

Interventionpercentage of patients alive (Number)
High Risk - Treated With Alternating R-CODOX-M/R-IVAC81
Low Risk - Treatment With 3 Cycles of R-CODOX-M100

Progression Free Survival (PFS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen

Progression Free Survival (PFS) will be defined from the first dose of study drug to the first documentation of progressive disease or death for any reason. Patients that are lost to follow-up before progression will be censored at the point of last documentation of not experiencing the event. (NCT00392990)
Timeframe: At 2 years from treatment initiation. Median follow up 34 months (range 15-45)

Interventionpercentage of patients progression free (Number)
High Risk - Treated With Alternating R-CODOX-M/R-IVAC76
Low Risk - Treatment With 3 Cycles of R-CODOX-M100

Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen

"Response Rate is defined as combined number of patients with Complete Remission (CR) Complete Remission undetermined (Cru) and Partial Remission (PR) for patients with Burkitt's and Burkitt-like Lymphoma/Leukemia. Response will be measured by CT scans following treatment completion and assessed using Response Criteria for Non-Hodgkin's Lymphoma where:~CR=complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms.~CRu=same as above but allowing for 75% decrease in lymph node masses and indeterminate or normal bone marrow.~PR=50% decrease in SPD of the six largest dominant nodes or nodal masses with no increase in size or other nodes, liver, spleen and no new sites of disease." (NCT00392990)
Timeframe: After two cycles of treatment and at completion of treatment (4 cycles for high risk and 3 cycles for low risk) up to approximately 20 weeks.

,
Interventionpercentage of patients (Number)
ORR after two cycles of treatmentORR at completion of treatment
High Risk - Treated With Alternating R-CODOX-M/R-IVAC100100
Low Risk - Treatment With 3 Cycles of R-CODOX-M100100

Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate)

"Adverse events (AE) graded as either 3 or 4 and determined to be at least possibly related to study treatment will be collected in patients Burkitt's and Burkitt-like Lymphoma/Leukemia treated with modified Magrath regimen to assess the safety and toxicity profile of the addition of rituximab, subsitution of adriamycin for doxil and lower dose of methotrexate. AEs will be assessed as follows at the following time points: At the end of each cycle or monthly whichever is less frequent and 30 days post last dose of study treatment for a maximum of 3 cycles for regimen A and 4 cycles for regimen B and up to 12 months.~In general AEs will be assessed according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v 3.0). In general adverse events (AEs) will be graded according to the following:~Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE" (NCT00392990)
Timeframe: After each cycle or monthly (whichever is less frequent), 30 days post last dose. Treatment duration was at a median of 13 weeks (range 11-20) for high-risk patients and 10 weeks (range 9-12) for low-risk patients.

,
Interventionparticipants (Number)
Anemia : Grade 3Anemia : Grade 4Neutropenia : Grade 3Neutropenia : Grade 4Thrombocytopenia : Grade 3Thrombocytopenia : Grade 4Mucositis : Grade 3Mucositis : Grade 4Infection : Grade 3Infection : Grade 4Elevated Transaminases : Grade 3Elevated Transaminases : Grade 4Fever (Neutropenic) : Grade 3Fever (Neutropenic) : Grade 4Low Phosphate : Grade 3Low Phosphate : Grade 4Sodium Abnormalities : Grade 3Sodium Abnormalities : Grade 4Hyperglycemia : Grade 3Hyperglycemia : Grade 4Hypoalbuminemia : Grade 3Hypoalbuminemia : Grade 4Hypokalemia : Grade 3Hypokalemia : Grade 4Cardiac : Grade 3Cardiac : Grade 4Diarrhea : Grade 3Diarrhea : Grade 4Elevated Creatinine : Grade 3Elevated Creatinine : Grade 4Nausea/Vomiting : Grade 3Nausea/Vomiting : Grade 4Low Blood Pressure : Grade 3Low Blood Pressure : Grade 4Rash : Grade 3Rash : Grade 4Edema : Grade 3Edema : Grade 4Low Magnesium : Grade 3Low Magnesium : Grade 4
High Risk - Treated With Alternating R-CODOX-M/R-IVAC131561137380604050401540103020201010101010
Low Risk - Treatment With 3 Cycles of R-CODOX-M3022122010203010203000200000000000000000

Reviews

5 reviews available for ifosfamide and Thrombopenia

ArticleYear
The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis.
    Journal of orthopaedic surgery and research, 2020, Feb-13, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Do

2020
The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
    Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinica

1995
The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
    Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Ifosfamide; L

1995
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Neoadjuvant therapy for cervical cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

1992

Trials

53 trials available for ifosfamide and Thrombopenia

ArticleYear
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Cancer medicine, 2020, Volume: 9, Issue:16

    Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 R

2020
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Drug Administ

2018
Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide.
    BMC cancer, 2013, Mar-16, Volume: 13

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Dose-

2013
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols;

2013
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placeb
    Leukemia & lymphoma, 2015, Volume: 56, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carb

2015
[DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro

2008
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Feasibility Stu

2009
[Efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents].
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid

2009
Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Anti-cancer drugs, 2010, Volume: 21, Issue:3

    Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Brain Injuries;

2010
Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia.
    BMC cancer, 2010, Oct-19, Volume: 10

    Topics: Adult; Aged; Antineoplastic Agents; Blood Platelets; Dacarbazine; Dose-Response Relationship, Drug;

2010
Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-15, Volume: 21, Issue:16

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies

2003
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
    British journal of cancer, 2004, Jun-14, Volume: 90, Issue:12

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; D

2004
Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2004, Volume: 20, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Th

2004
Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
    British journal of haematology, 2005, Volume: 128, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch

2005
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-01, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Ant

2005
Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:2

    Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bo

2005
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
    Oncology, 2005, Volume: 69, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free

2005
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
    Oncology reports, 2005, Volume: 14, Issue:6

    Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-

2005
Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carb

1995
Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
    Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cispl

1995
A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
    Seminars in oncology, 1995, Volume: 22, Issue:4 Suppl 9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, No

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dose-Response Relatio

1995
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasibility Studies; Femal

1994
A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Germinoma; Granulocyte-Macroph

1993
A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell carcinoma of the uterine cervix.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

1993
A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
    Cancer, 1993, Jul-01, Volume: 72, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat

1993
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch

1993
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:3

    Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch

1996
High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
    Bone marrow transplantation, 1996, Volume: 17, Issue:2

    Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow;

1996
Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
    The Journal of infusional chemotherapy, 1996,Winter, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia; Antineoplastic Combined Che

1996
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.
    Cancer, 1996, Aug-15, Volume: 78, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp

1996
Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
    Gynecologic oncology, 1996, Volume: 63, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Combined Mod

1996
Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Cancer, 1998, Jan-15, Volume: 82, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineo

1998
Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study.
    International journal of radiation oncology, biology, physics, 1998, Jan-15, Volume: 40, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cohor

1998
Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
    Gynecologic oncology, 1998, Volume: 68, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carb

1998
High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasib

1998
Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie Clini
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined M

1999
Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
    Journal of cancer research and clinical oncology, 1999, Volume: 125, Issue:12

    Topics: Adolescent; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ch

1999
Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
    British journal of cancer, 2000, Volume: 82, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship,

2000
A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
    Cancer, 2000, Jun-15, Volume: 88, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati

2000
Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: a phase II study of the italian oncology group for clinical research (GOIRC).
    International journal of cancer, 2000, Sep-01, Volume: 87, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat

2000
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
    British journal of cancer, 2000, Volume: 83, Issue:9

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-S

2000
High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy.
    Leukemia & lymphoma, 2000, Volume: 37, Issue:5-6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirub

2000
Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2000, Volume: 30, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat

2000
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer.
    British journal of cancer, 2001, Jan-05, Volume: 84, Issue:1

    Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Sma

2001
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
    Medical and pediatric oncology, 2001, Volume: 36, Issue:1

    Topics: Adolescent; Amifostine; Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Cell Divi

2001
Dose-finding and pharmacological study of ifosfamide in combination with paclitaxel and carboplatin in resistant small-cell lung cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carb

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid

2001
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:10

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; He

2001
Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-15, Volume: 20, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Disease-Fr

2002
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
    Cancer, 2002, Feb-01, Volume: 94, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined

2002
Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724).
    European journal of cancer, 1976, Volume: 12, Issue:3

    Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Hematuria; Humans; Ifosfamide; Kidney Tubul

1976
Neoadjuvant therapy for cervical cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

1992

Other Studies

28 other studies available for ifosfamide and Thrombopenia

ArticleYear
Splenic embolization to continue chemotherapy in a child with hypersplenism-related thrombocytopenia.
    Pediatric blood & cancer, 2021, Volume: 68, Issue:2

    Topics: Antineoplastic Agents; Child; Cyclophosphamide; Desmoplastic Small Round Cell Tumor; Doxorubicin; Em

2021
Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:3

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doce

2015
Effects and toxicity of neoadjuvant chemotherapy preoperative followed by adjuvant chemoradiation in small cell neurdendocrine cervical carcinoma.
    European journal of gynaecological oncology, 2015, Volume: 36, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Neuroendo

2015
[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:8

    Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytid

2015
Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2011
Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
    Cancer, 2012, Feb-15, Volume: 118, Issue:4

    Topics: Adolescent; Age Factors; Anemia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc

2012
Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency.
    Thrombosis research, 2002, Apr-15, Volume: 106, Issue:2

    Topics: ADAM Proteins; ADAMTS13 Protein; Adenocarcinoma; Anemia, Hemolytic; Antineoplastic Combined Chemothe

2002
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
    European journal of haematology, 2003, Volume: 70, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine

2003
[Paclitaxel, ifosfamide, nedaplatin (TIN) for patients with metastatic urothelial cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans;

2004
[Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2005, Volume: 24, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Dexametha

2005
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; F

2005
[MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2005, Volume: 24, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Drug Resistance, Neo

2005
[Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2006, Volume: 97, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sc

2006
[Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F

2006
[Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:12

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carbo

2006
[Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2006
Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Alopecia; Brain; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Hematuria; Humans;

1982
Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide.
    Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Etoposide; Female; F

1995
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agen

1996
[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms;

1998
A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer.
    Journal of chemotherapy (Florence, Italy), 2001, Volume: 13, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deo

2001
Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Administra

1992
[Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Female; Hea

1991
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio

1990
Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Com

1990
Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat

1990
VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Humans; Ifosfamide; Kidn

1986
Ifosfamide chemotherapy for pancreatic carcinoma.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Acetylcysteine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfam

1986